Skip to main content
AAN.com

Abstract

Objective:

To investigate prospective, population-based long-term outcomes concerning seizures and antiepileptic drug (AED) treatment after resective epilepsy surgery in Sweden.

Methods:

Ten- and 5-year follow-ups were performed in 2005 to 2007 for 278/327 patients after resective epilepsy surgery from 1995 to 1997 and 2000 to 2002, respectively. All patients had been prospectively followed in the Swedish National Epilepsy Surgery Register. Ninety-three patients, who were presurgically evaluated but not operated, served as controls.

Results:

In the long term (mean 7.6 years), 62% of operated adults and 50% of operated children were seizure-free, compared to 14% of nonoperated adults (p < 0.001) and 38% of nonoperated children (not significant). Forty-one percent of operated adults and 44% of operated children had sustained seizure freedom since surgery, compared to none of the controls (p < 0.0005). Multivariate analysis identified ≥30 seizures/month at baseline and long epilepsy duration as negative predictors and positive MRI to be a positive predictor of long-term seizure-free outcome. Ten years after surgery, 86% of seizure-free children and 43% of seizure-free adults had stopped AEDs in the surgery groups compared to none of the controls (p < 0.0005).

Conclusions:

This population-based, prospective study shows good long-term seizure outcomes after resective epilepsy surgery. The majority of the patients who are seizure-free after 5 and 10 years have sustained seizure freedom since surgery. Many patients who gain seizure freedom can successfully discontinue AEDs, more often children than adults.

Classification of evidence:

This study provides Class III evidence that more patients are seizure-free and have stopped AED treatment in the long term after resective epilepsy surgery than nonoperated epilepsy patients.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (figure_e-1.pdf)
File (table_e-1.pdf)
File (table_e-2.pdf)

REFERENCES

1.
Wiebe S, Blume WT, Girvin JP, Eliasziw M. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 2001;345:311–318.
2.
Engel J, McDermott MP, Wiebe S, et al. Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. JAMA 2012;307:922–930.
3.
Tellez-Zenteno JF, Dhar R, Wiebe S. Long-term seizure outcomes following epilepsy surgery: a systematic review and meta-analysis. Brain 2005;128:1188–1198.
4.
McIntosh AM, Kalnins RM, Mitchell LA, Fabinyi GC, Briellmann RS, Berkovic SF. Temporal lobectomy: long-term seizure outcome, late recurrence and risks for seizure recurrence. Brain 2004;127:2018–2030.
5.
de Tisi J, Bell GS, Peacock JL, et al. The long-term outcome of adult epilepsy surgery, patterns of seizure remission, and relapse: a cohort study. Lancet 2011;378:1388–1395.
6.
Luoni C, Bisulli F, Canevini MP, et al. Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. Epilepsia 2011;52:2181–2191.
7.
Wilson SJ, Saling MM, Kincade P, Bladin PF. Patient expectations of temporal lobe surgery. Epilepsia 1998;39:167–174.
8.
Boshuisen K, Arzimanoglou A, Cross JH, et al. Timing of antiepileptic drug withdrawal and long-term seizure outcome after paediatric epilepsy surgery (TimeToStop): a retrospective observational study. Lancet Neurol 2012;11:784–791.
9.
Rydenhag B, Silander HC. Complications of epilepsy surgery after 654 procedures in Sweden, September 1990-1995: a multicenter study based on the Swedish National Epilepsy Surgery Register. Neurosurgery 2001;49:51–56; discussion 56–57.
10.
Malmgren K, Olsson I, Engman E, Flink R, Rydenhag B. Seizure outcome after resective epilepsy surgery in patients with low IQ. Brain 2008;131:535–542.
11.
Rydenhag B, Flink R, Malmgren K. Surgical outcomes in patients with epileptogenic tumours and cavernomas in Sweden: good seizure control but late referrals. J Neurol Neurosurg Psychiatry 2013;84:49–53.
12.
Wieser HG, Blume WT, Fish D, et al. ILAE Commission Report: proposal for a new classification of outcome with respect to epileptic seizures following epilepsy surgery. Epilepsia 2001;42:282–286.
13.
Beghi E, Tonini C. Surgery for epilepsy: assessing evidence from observational studies. Epilepsy Res 2006;70:97–102.
14.
Engel J. Outcome with respect to epileptic seizures. In: Surgical Treatment of the Epilepsies. New York: Raven Press; 1993:609–621.
15.
Cohen-Gadol AA, Wilhelmi BG, Collignon F, et al. Long-term outcome of epilepsy surgery among 399 patients with nonlesional seizure foci including mesial temporal lobe sclerosis. J Neurosurg 2006;104:513–524.
16.
Elsharkawy AE, Alabbasi AH, Pannek H, et al. Long-term outcome after temporal lobe epilepsy surgery in 434 consecutive adult patients. J Neurosurg 2009;110:1135–1146.
17.
Mihara T, Matsuda K, Tottori T, et al. Long-term seizure outcome following resective surgery at National Epilepsy Center in Shizuoka, Japan. Psychiatry Clin Neurosci 2004;58:S22–S25.
18.
Dupont S, Tanguy ML, Clemenceau S, Adam C, Hazemann P, Baulac M. Long-term prognosis and psychosocial outcomes after surgery for MTLE. Epilepsia 2006;47:2115–2124.
19.
Sindou M, Guenot M, Isnard J, Ryvlin P, Fischer C, Mauguiere F. Temporo-mesial epilepsy surgery: outcome and complications in 100 consecutive adult patients. Acta Neurochir 2006;148:39–45.
20.
Paglioli E, Palmini A, da Costa JC, et al. Survival analysis of the surgical outcome of temporal lobe epilepsy due to hippocampal sclerosis. Epilepsia 2004;45:1383–1391.
21.
Aull-Watschinger S, Pataraia E, Czech T, Baumgartner C. Outcome predictors for surgical treatment of temporal lobe epilepsy with hippocampal sclerosis. Epilepsia 2008;49:1308–1316.
22.
Jeha LE, Najm IM, Bingaman WE, et al. Predictors of outcome after temporal lobectomy for the treatment of intractable epilepsy. Neurology 2006;66:1938–1940.
23.
Aaberg K, Eriksson AS, Ramm-Pettersen J, Nakken K. Long-term outcome of resective epilepsy surgery in Norwegian children. Acta Paediatr 2012;101:e557–e560.
24.
Benifla M, Rutka JT, Otsubo H, et al. Long-term seizure and social outcomes following temporal lobe surgery for intractable epilepsy during childhood. Epilepsy Res 2008;82:133–138.
25.
Boshuisen K, Braams O, Jennekens-Schinkel A, et al. Medication policy after epilepsy surgery. Pediatr Neurol 2009;41:332–338.
26.
Mittal S, Montes JL, Farmer JP, et al. Long-term outcome after surgical treatment of temporal lobe epilepsy in children. J Neurosurg 2005;103:401–412.
27.
Sinclair DB, Aronyk KE, Snyder TJ, et al. Pediatric epilepsy surgery at the University of Alberta: 1988-2000. Pediatr Neurol 2003;29:302–311.
28.
Van Oijen M, De Waal H, Van Rijen PC, Jennekens-Schinkel A, van Huffelen AC, Van Nieuwenhuizen O. Resective epilepsy surgery in childhood: the Dutch experience 1992-2002. Eur J Paediatr Neurol 2006;10:114–123.
29.
Lopez-Gonzalez MA, Gonzalez-Martinez JA, Jehi L, Kotagal P, Warbel A, Bingaman W. Epilepsy surgery of the temporal lobe in pediatric population: a retrospective analysis. Neurosurgery 2012;70:684–692.
30.
McIntosh AM, Averill CA, Kalnins RM, et al. Long-term seizure outcome and risk factors for recurrence after extratemporal epilepsy surgery. Epilepsia 2012;53:970–978.
31.
Jeha LE, Najm I, Bingaman W, Dinner D, Widdess-Walsh P, Luders H. Surgical outcome and prognostic factors of frontal lobe epilepsy surgery. Brain 2007;130:574–584.
32.
Elsharkawy AE, Alabbasi AH, Pannek H, et al. Outcome of frontal lobe epilepsy surgery in adults. Epilepsy Res 2008;81:97–106.
33.
Dunlea O, Doherty CP, Farrell M, et al. The Irish epilepsy surgery experience: long-term follow-up. Seizure 2010;19:247–252.
34.
Schmidt D, Stavem K. Long-term seizure outcome of surgery versus no surgery for drug-resistant partial epilepsy: a review of controlled studies. Epilepsia 2009;50:1301–1309.
35.
Schwartz TH, Jeha L, Tanner A, Bingaman W, Sperling MR. Late seizures in patients initially seizure free after epilepsy surgery. Epilepsia 2006;47:567–573.
36.
Menon R, Rathore C, Sarma SP, Radhakrishnan K. Feasibility of antiepileptic drug withdrawal following extratemporal resective epilepsy surgery. Neurology 2012;79:770–776.
37.
Simasathien T, Vadera S, Najm I, Gupta A, Bingaman W, Jehi L. Improved outcomes with earlier surgery for intractable frontal lobe epilepsy. Ann Neurol 2013;73:646–654.
38.
Tellez-Zenteno JF, Dhar R, Hernandez-Ronquillo L, Wiebe S. Long-term outcomes in epilepsy surgery: antiepileptic drugs, mortality, cognitive and psychosocial aspects. Brain 2007;130:334–345.
39.
Rathore C, Panda S, Sarma PS, Radhakrishnan K. How safe is it to withdraw antiepileptic drugs following successful surgery for mesial temporal lobe epilepsy? Epilepsia 2011;52:627–635.
40.
Jacoby A, Baker G, Chadwick D, Johnson A. The impact of counselling with a practical statistical model on patient's decision-making about treatment for epilepsy: findings from a pilot study. Epilepsy Res 1993;16:207–214.

Information & Authors

Information

Published In

Neurology®
Volume 81Number 14October 1, 2013
Pages: 1244-1251
PubMed: 23966252

Publication History

Received: December 26, 2012
Accepted: July 2, 2013
Published online: August 21, 2013
Published in print: October 1, 2013

Permissions

Request permissions for this article.

Disclosure

A. Edelvik received speaker honoraria from UCB and Eisai. B. Rydenhag, I. Olsson, and R. Flink report no disclosures. E. Kumlien served on a scientific advisory board for GlaxoSmithKline. K. Källén served on scientific advisory boards for Eisai and GlaxoSmithKline. K. Malmgren served on an educational advisory board for UCB and has received speaker's honoraria from UCB. Go to Neurology.org for full disclosures.

Study Funding

Funded by grants from the Swedish Research Council (grant 521-2011-169), the Sahlgrenska Academy at Gothenburg University through the LUA/ALF agreement (grant ALFGBG137431), the Gothenburg Foundation for Neurological Research, the Gothenburg Medical Society, the Margaretahem Foundation, and an unconditional research grant from GlaxoSmithKline to Anna Edelvik.

Authors

Affiliations & Disclosures

Anna Edelvik, MD
From the Epilepsy Research Group, Institute of Neuroscience and Physiology (A.E., B.R., K.M.), and Department of Paediatrics, Institute of Clinical Sciences (I.O.), Sahlgrenska Academy at Gothenburg University; Departments of Clinical Neurophysiology (R.F.) and Neurology (E.K.), Uppsala University Hospital; and Department of Neurology (K.K.), Institution of Clinical Neurosciences, Lund University, Sweden.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Speaker honoraria from UCB and Eisai in 2010 and 2011.
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Unconditional grant from GlaxoSmithKline in 2008.
Research Support, Government Entities:
1.
Swedish Research Council, grant no. 521-2011-169. Sahlgrenska Academy at Gothenburg University, grant ALFGBG137431.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Gothenburg Foundation for Neurological Research. Gothenburg Medical Society.
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Bertil Rydenhag, MD, PhD
From the Epilepsy Research Group, Institute of Neuroscience and Physiology (A.E., B.R., K.M.), and Department of Paediatrics, Institute of Clinical Sciences (I.O.), Sahlgrenska Academy at Gothenburg University; Departments of Clinical Neurophysiology (R.F.) and Neurology (E.K.), Uppsala University Hospital; and Department of Neurology (K.K.), Institution of Clinical Neurosciences, Lund University, Sweden.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Ingrid Olsson, MD, PhD
From the Epilepsy Research Group, Institute of Neuroscience and Physiology (A.E., B.R., K.M.), and Department of Paediatrics, Institute of Clinical Sciences (I.O.), Sahlgrenska Academy at Gothenburg University; Departments of Clinical Neurophysiology (R.F.) and Neurology (E.K.), Uppsala University Hospital; and Department of Neurology (K.K.), Institution of Clinical Neurosciences, Lund University, Sweden.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Roland Flink, MD, PhD
From the Epilepsy Research Group, Institute of Neuroscience and Physiology (A.E., B.R., K.M.), and Department of Paediatrics, Institute of Clinical Sciences (I.O.), Sahlgrenska Academy at Gothenburg University; Departments of Clinical Neurophysiology (R.F.) and Neurology (E.K.), Uppsala University Hospital; and Department of Neurology (K.K.), Institution of Clinical Neurosciences, Lund University, Sweden.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Eva Kumlien, MD, PhD
From the Epilepsy Research Group, Institute of Neuroscience and Physiology (A.E., B.R., K.M.), and Department of Paediatrics, Institute of Clinical Sciences (I.O.), Sahlgrenska Academy at Gothenburg University; Departments of Clinical Neurophysiology (R.F.) and Neurology (E.K.), Uppsala University Hospital; and Department of Neurology (K.K.), Institution of Clinical Neurosciences, Lund University, Sweden.
Disclosure
Scientific Advisory Boards:
1.
Scientific advisory board for GlaxoSmithKline 2010-2012 and Eisai 2010 -
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Kristina Källén, MD, PhD
From the Epilepsy Research Group, Institute of Neuroscience and Physiology (A.E., B.R., K.M.), and Department of Paediatrics, Institute of Clinical Sciences (I.O.), Sahlgrenska Academy at Gothenburg University; Departments of Clinical Neurophysiology (R.F.) and Neurology (E.K.), Uppsala University Hospital; and Department of Neurology (K.K.), Institution of Clinical Neurosciences, Lund University, Sweden.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Kristina Malmgren, MD, PhD
From the Epilepsy Research Group, Institute of Neuroscience and Physiology (A.E., B.R., K.M.), and Department of Paediatrics, Institute of Clinical Sciences (I.O.), Sahlgrenska Academy at Gothenburg University; Departments of Clinical Neurophysiology (R.F.) and Neurology (E.K.), Uppsala University Hospital; and Department of Neurology (K.K.), Institution of Clinical Neurosciences, Lund University, Sweden.
Disclosure
Scientific Advisory Boards:
1.
UCB, committee for educational program 2009-10
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Received travel expenses and/or honoraria for lectures or educational activities not funded by industry
Editorial Boards:
1.
Member of editorial board of Seizure since 2005
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Received speaker's honoraria from UCB 2010-2011
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Institutional funding through the LUA/ALF agreement, grant no ALFGBG-11284 2008-2010 and from the Swedish Research Council (grant 521-2011-169)
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Research grants from the Margarethahem foundation 2008 and 2009
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Correspondence to Dr. Malmgren: [email protected]
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Author Contributions

Dr. Edelvik has analyzed and interpreted the data and written the manuscript. Dr. Rydenhag has analyzed and interpreted the data and revised the manuscript. Dr Olsson has interpreted the data and revised the manuscript. Dr. Flink is manager of the Swedish Epilepsy Surgery Register and assisted with data analysis. Dr. Kumlien and Dr. Källén have analyzed and interpreted the data concerning the nonoperated controls. Dr. Malmgren has designed the study, interpreted data, and written the manuscript.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Drug-resistant epilepsy: Current concepts, pathogenesis, risk factors, outcomes of surgical treatment, Acta Biomedica Scientifica, 9, 3, (153-163), (2024).https://doi.org/10.29413/ABS.2024-9.3.15
    Crossref
  2. Epilepsy surgery in adults older than 50 years: A systematic review and meta‐analysis, Epilepsia, 65, 6, (1548-1559), (2024).https://doi.org/10.1111/epi.17972
    Crossref
  3. Delays in the diagnosis and surgical treatment of drug‐resistant epilepsy: A cohort study, Epilepsia, 65, 5, (1314-1321), (2024).https://doi.org/10.1111/epi.17944
    Crossref
  4. Postoperative seizure outcomes and antiseizure medication utilization based on histopathological diagnosis: A retrospective cohort study, Epilepsy & Behavior, 161, (110056), (2024).https://doi.org/10.1016/j.yebeh.2024.110056
    Crossref
  5. Advocacy for Epilepsy Surgery in Africa: Moroccan Experience of 132 Cases, World Neurosurgery, 183, (e421-e431), (2024).https://doi.org/10.1016/j.wneu.2023.12.115
    Crossref
  6. Treatment odyssey to epilepsy surgery in children with focal cortical dysplasia: Risk factors for delayed surgical intervention, Seizure: European Journal of Epilepsy, 120, (5-11), (2024).https://doi.org/10.1016/j.seizure.2024.06.007
    Crossref
  7. Dominant, Lesional Pediatric-Onset Hemispheric Epilepsy, Epilepsy Surgery: A Practical Case-Based Approach, (533-562), (2024).https://doi.org/10.1007/978-3-031-23828-4_22
    Crossref
  8. Non-dominant, Lesional Frontal Lobe Epilepsy Masquerading as Generalized Epilepsy, Epilepsy Surgery: A Practical Case-Based Approach, (339-359), (2024).https://doi.org/10.1007/978-3-031-23828-4_15
    Crossref
  9. The Utility of Responsive Neurostimulation for the Treatment of Pediatric Drug-Resistant Epilepsy, Brain Sciences, 13, 10, (1455), (2023).https://doi.org/10.3390/brainsci13101455
    Crossref
  10. Candidate Selection for Implantation: Noninvasive Predictors of Seizure Onset Zone Focality and Surgical Outcome in People with Drug-Resistant Epilepsy Evaluated by Intracranial Video-EEG Monitoring—A Retrospective Cohort Study, Acta Neurologica Scandinavica, 2023, (1-11), (2023).https://doi.org/10.1155/2023/3455061
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share